Wedbush Maintains Outperform on Rezolute, Raises Price Target to $10
Wedbush analyst Yun Zhong maintains Rezolute (NASDAQ:RZLT) with a Outperform and raises the price target from $6 to $10.
Last updated: 2026-11-18 14:05:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Rezolute, Inc. (RZLT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.03, with a market capitalization of $346.29M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.07 to $11.17. This page covers its latest market performance, valuation, price trends and company information.
$346.29M | |
$4.01 | |
$4.10 | |
$4.01 | |
$4.01 | |
1.85K | |
1.69M | |
-- | |
$11.17 | |
$1.07 | |
-- | |
2026-09-30 |
Rezolute, Inc. (RZLT) is trading at $4.03 in pre-market trading as of 2026-11-18 13:53:00, up 0.25% ($0.01) from the previous close of $4.02
Pre-market trading shows how investors are pricing RZLT before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
RZLT is up 0.25% in pre-market trading.
Over the past seven days, Rezolute, Inc. (RZLT) moved from $3.87 to $4.03, representing a gain of 4.01% ($0.16).
The stock traded between $3.37 and $4.61 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 2.71 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 29.3%
RZLT is currently trading at $4.03, placing it 29.3% of the way from its 52-week low of $1.07 to its 52-week high of $11.17. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 58 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Rezolute, Inc. and RZLT stock.
Wedbush analyst Yun Zhong maintains Rezolute (NASDAQ:RZLT) with a Outperform and raises the price target from $6 to $10.
Rezolute achieves its Phase 3 primary endpoint for ersodetug in tumor hyperinsulinism and prices a $100 million equity offering.
Gainers SELLAS Life Sciences Gr (NASDAQ:SLS) stock rose 19.6% to $9.6 during Friday's pre-market session. The market value of their outstanding shares is at $1.6 billion. As per the news, the Q3 earnings report
Underwritten offering of 22,040,976 shares of its common stock at an offering price of $3.87 per share, and to certain investors in lieu of common stock, pre-funded warrants to purchase up to 3,800,000 shares of common
The primary efficacy endpoint in the upLIFT study is the proportion of patients able to achieve at least a 50% reduction from baseline in glucose infusion rate (GIR), a measure of intravenous glucose dependency for
Eligible investors can buy real shares of Rezolute, Inc. (RZLT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to RZLT, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between RZLT shares and USD.
RZLT Shares to USD
1.00 RZLT shares = 4.025 USD
Calculations are estimates based on the latest available price and are for reference only.